



3-29-7

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re application of:

**Frederic COLLAND, et al.**

Application No. **10/520,712**

Filed: **December 22, 2005**

For: **USE OF SPECIFIED TCF TARGET GENES TO IDENTIFY DRUGS FOR THE TREATMENT OF CANCER, IN PARTICULAR COLORECTAL CANCER, IN WHICH TCF/SS-CATENIN/WNT SIGNALLING PLAYS A CENTRAL ROLE**

Art Unit: **1642**

Examiner: **Goddard, Laura B.**

Docket No.: **67670-5005-01-US**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**CHANGE OF CORRESPONDENCE ADDRESS**

Sir:

Please change the correspondence address to the address indicated below, and address all correspondence to Richard F. Trecartin:


**Customer Number 67374**

Currently:

MORGAN, LEWIS & BOCKIUS LLP  
One Market, Spear Street Tower  
San Francisco, California 94105  
Tel: 415.442.1000  
Fax: 415.442.1001

MORGAN, LEWIS & BOCKIUS LLP

Date: March 23, 2007

By:   
Richard F. Trecartin, Reg. No. 31,801  
Attorney for Applicant  
Filed under 37 C.F.R. § 1.34

MORGAN, LEWIS & BOCKIUS LLP  
One Market, Spear Street Tower  
San Francisco, California 94105  
Tel: 415.442.1000  
Fax: 415.442.1001